Switch to:
Also traded in: Australia, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
AVMXY's Cash-to-Debt is ranked higher than
93% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. AVMXY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
AVMXY' s Cash-to-Debt Range Over the Past 10 Years
Min: 16.69  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.92
AVMXY's Equity-to-Asset is ranked higher than
97% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. AVMXY: 0.92 )
Ranked among companies with meaningful Equity-to-Asset only.
AVMXY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.91 Max: 0.99
Current: 0.92
0.51
0.99
Interest Coverage No Debt
AVMXY's Interest Coverage is ranked higher than
93% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: 93.54 vs. AVMXY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AVMXY' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -0.12
WACC vs ROIC
4.49%
-700.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -1420.82
AVMXY's Operating Margin % is ranked lower than
94% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. AVMXY: -1420.82 )
Ranked among companies with meaningful Operating Margin % only.
AVMXY' s Operating Margin % Range Over the Past 10 Years
Min: -1723.37  Med: -288.3 Max: -178.34
Current: -1420.82
-1723.37
-178.34
Net Margin % -779.39
AVMXY's Net Margin % is ranked lower than
91% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. AVMXY: -779.39 )
Ranked among companies with meaningful Net Margin % only.
AVMXY' s Net Margin % Range Over the Past 10 Years
Min: -1614.68  Med: -242.44 Max: -57.58
Current: -779.39
-1614.68
-57.58
ROE % -84.29
AVMXY's ROE % is ranked lower than
84% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 2.08 vs. AVMXY: -84.29 )
Ranked among companies with meaningful ROE % only.
AVMXY' s ROE % Range Over the Past 10 Years
Min: -145.87  Med: -87.94 Max: -17.34
Current: -84.29
-145.87
-17.34
ROA % -71.80
AVMXY's ROA % is ranked lower than
82% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. AVMXY: -71.80 )
Ranked among companies with meaningful ROA % only.
AVMXY' s ROA % Range Over the Past 10 Years
Min: -111.43  Med: -65.83 Max: -13.45
Current: -71.8
-111.43
-13.45
ROC (Joel Greenblatt) % -592.08
AVMXY's ROC (Joel Greenblatt) % is ranked lower than
80% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 4.02 vs. AVMXY: -592.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AVMXY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4361.27  Med: -834.71 Max: -248.87
Current: -592.08
-4361.27
-248.87
3-Year Revenue Growth Rate -39.40
AVMXY's 3-Year Revenue Growth Rate is ranked lower than
90% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. AVMXY: -39.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AVMXY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -33.3 Max: 8.7
Current: -39.4
0
8.7
3-Year EBITDA Growth Rate -5.20
AVMXY's 3-Year EBITDA Growth Rate is ranked lower than
69% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. AVMXY: -5.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AVMXY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.1  Med: -14.35 Max: 30.8
Current: -5.2
-64.1
30.8
3-Year EPS without NRI Growth Rate -8.00
AVMXY's 3-Year EPS without NRI Growth Rate is ranked lower than
66% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. AVMXY: -8.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AVMXY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.9  Med: -17.5 Max: 11.9
Current: -8
-57.9
11.9
GuruFocus has detected 5 Warning Signs with Avita Medical Ltd $AVMXY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AVMXY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with AVMXY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices  
Compare:NAS:VIVE, NAS:SPAN, NAS:SRTS, NAS:AVGR, NAS:TNDM, NAS:NVTR, OTCPK:QTVLF, OTCPK:BTCY, OTCPK:TITXF, NAS:ETRM, NAS:EYES, AMEX:ELMD, NAS:MGCD, OTCPK:BLOZF, OTCPK:RMSL, NAS:EDAP, OTCPK:VICA, OTCPK:BSGM, NAS:RWLK, OTCPK:DIZTF » details
Traded in other countries:AVH.Australia, GCR.Germany,
Avita Medical Ltd is a medical device company. It develops and sells regenerative and respiratory medicine. It offers products such as ReCell Autologous Spray-On-Skin, Funhaler incentive asthma spacer and Breath-A-Tech spacer.

Avita Medical Ltd. manufactures & sells regenerative & respiratory medical devices. It offers tissue-engineered products for wound & skin defects, spacers for adolescent & adults, ReCell Spray-On-Skin, Funhaler for asthma & Breath-ATech, among others.

Ratios

vs
industry
vs
history
PB Ratio 5.83
AVMXY's PB Ratio is ranked lower than
76% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.35 vs. AVMXY: 5.83 )
Ranked among companies with meaningful PB Ratio only.
AVMXY' s PB Ratio Range Over the Past 10 Years
Min: 0.21  Med: 2.56 Max: 15
Current: 5.83
0.21
15
PS Ratio 46.68
AVMXY's PS Ratio is ranked lower than
94% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.31 vs. AVMXY: 46.68 )
Ranked among companies with meaningful PS Ratio only.
AVMXY' s PS Ratio Range Over the Past 10 Years
Min: 1.43  Med: 9.29 Max: 70
Current: 46.68
1.43
70
Current Ratio 11.89
AVMXY's Current Ratio is ranked higher than
96% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. AVMXY: 11.89 )
Ranked among companies with meaningful Current Ratio only.
AVMXY' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 5.62 Max: 195.06
Current: 11.89
0.02
195.06
Quick Ratio 10.79
AVMXY's Quick Ratio is ranked higher than
96% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. AVMXY: 10.79 )
Ranked among companies with meaningful Quick Ratio only.
AVMXY' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 5.07 Max: 195.06
Current: 10.79
0.02
195.06
Days Inventory 1.00
AVMXY's Days Inventory is ranked higher than
99% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 125.58 vs. AVMXY: 1.00 )
Ranked among companies with meaningful Days Inventory only.
AVMXY' s Days Inventory Range Over the Past 10 Years
Min: 1  Med: 358.08 Max: 892.52
Current: 1
1
892.52
Days Sales Outstanding 728.08
AVMXY's Days Sales Outstanding is ranked lower than
100% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. AVMXY: 728.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVMXY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 98.69  Med: 179.48 Max: 736.19
Current: 728.08
98.69
736.19
Days Payable 737.80
AVMXY's Days Payable is ranked higher than
99% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. AVMXY: 737.80 )
Ranked among companies with meaningful Days Payable only.
AVMXY' s Days Payable Range Over the Past 10 Years
Min: 112.97  Med: 328.22 Max: 1400.07
Current: 737.8
112.97
1400.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.40
AVMXY's 3-Year Average Share Buyback Ratio is ranked lower than
78% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. AVMXY: -17.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AVMXY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -93.8  Med: -36.9 Max: 0
Current: -17.4
-93.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.06
AVMXY's Price-to-Net-Cash is ranked higher than
64% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 15.26 vs. AVMXY: 9.06 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AVMXY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.93  Med: 4.19 Max: 50.5
Current: 9.06
0.93
50.5
Price-to-Net-Current-Asset-Value 4.67
AVMXY's Price-to-Net-Current-Asset-Value is ranked higher than
63% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. AVMXY: 4.67 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AVMXY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.67  Med: 4.5 Max: 33.67
Current: 4.67
0.67
33.67
Price-to-Tangible-Book 4.67
AVMXY's Price-to-Tangible-Book is ranked lower than
64% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.19 vs. AVMXY: 4.67 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AVMXY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.39  Med: 2.95 Max: 18.33
Current: 4.67
0.39
18.33
Price-to-Median-PS-Value 4.67
AVMXY's Price-to-Median-PS-Value is ranked lower than
99.99% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 1.07 vs. AVMXY: 4.67 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AVMXY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.43 Max: 13.26
Current: 4.67
0
13.26
Earnings Yield (Greenblatt) % -19.91
AVMXY's Earnings Yield (Greenblatt) % is ranked lower than
73% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: -0.81 vs. AVMXY: -19.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AVMXY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19.91  Med: 351.7 Max: 11345.6
Current: -19.91
-19.91
11345.6

More Statistics

Revenue (TTM) (Mil) $0.70
EPS (TTM) $ -0.21
Beta-0.12
Short Percentage of Float0.00%
52-Week Range $1.35 - 2.46
Shares Outstanding (Mil)33.65
» More Articles for AVMXY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Avita Medical to Present at Needham Healthcare Conference Mar 23 2017
Avita Medical to Present at Needham Healthcare Conference Mar 23 2017
Avita Medical to Present at Needham Healthcare Conference Mar 23 2017
Avita Announces Receipt of $975K R&D Tax Incentive Mar 15 2017
Avita Announces Receipt of $975K R&D Tax Incentive Mar 15 2017
Avita Announces Receipt of $975K R&D Tax Incentive Mar 15 2017
Avita Medical Announces Last Patient Visit in U.S. Pivotal Trial Mar 06 2017
Avita Medical Announces Last Patient Visit in U.S. Pivotal Trial Mar 06 2017
Avita Medical Announces Last Patient Visit in U.S. Pivotal Trial Mar 06 2017
Avita Medical Named to 2017 OTCQX Best 50 Feb 28 2017
Avita Medical Named to 2017 OTCQX Best 50 Feb 28 2017
Avita Medical Named to 2017 OTCQX Best 50 Feb 28 2017
Avita Medical CEO Shareholder Letter and Quarterly Report Jan 30 2017
Avita Medical CEO Shareholder Letter and Quarterly Report Jan 30 2017
Avita Medical CEO Shareholder Letter and Quarterly Report Jan 30 2017
Avita Medical to Participate in the 3rd Annual Biotech and Money / Medtech and Money London 2017... Jan 24 2017
Avita Medical to Participate in the 3rd Annual Biotech and Money / Medtech and Money London 2017... Jan 24 2017
Avita Medical to Participate in the 3rd Annual Biotech and Money / Medtech and Money London 2017... Jan 24 2017
Presentations at French Society of Plastic, Reconstructive and Aesthetic Surgery Reinforce Benefits... Nov 28 2016
AVITA MEDICAL, LTD. Financials Nov 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)